



A 360° approach to build Life Sciences partnerships



December
1st & 2nd - 2015
Strasbourg - France



Features

About BioFIT	p.2
Who will you meet	
Conference program	
Agenda	•
Hosted events	•

Organized by










About BioFIT 2015

BioFIT is the leading partnering event in Europe for Open Innovation, technology transfer and collaborative research in the field of Life Sciences.



About the organizers



Eurasanté is the economic development

agency focusing on biotech, nutrition and healthcare activities in Northern France. It assists French and foreign companies interested in developing their activities or setting-up a business in Northern France. Eurasanté provides many services such as aid in accessing public subsidies, support in real-estate research, assistance with administrative formalities, human resources services, market and regulatory expertise... It also promotes the Eurasanté Bio-business Park, which already hosts 7 hospitals, 4 universities, 7 specialized schools and more than 140 companies. It benefits from an exceptional location in the heart of Europe (near Paris, London, Brussels...).

www.eurasante.com



NHL Cluster is a dynamic network focusing on today's main health issues, at the crossroads of Nutrition,

Biotechnology, and Health. Its mission is to federate and support players in the Food and Health sectors in designing, developing, and financing the products and processes of the future. In the Health sector, NHL focuses on developing preventive, diagnostic, and therapeutic solutions applicable to cardiovascular and metabolic conditions, neurodegenerative diseases and Inflammatory Bowel Diseases (IBD). Its projects in the Food sector aim at protecting health and well-being through a safe, healthy, and sustainable diet.

www.nhl-cluster.com





As a French world-class cluster dedicated to therapeutic innovations, Alsace BioValley is the onestop contact to optimize any R&D development or

business project in Europe, both in drug development and medical technologies.

Located in Alsace region, part of the famous French-German-Swiss BioValley and with a unique concentration of international life sciences & healthcare players, Alsace BioValley helps any Life Sciences & Healthcare companies interested in new projects and partnerships in Europe: to search outstanding scientific or industrial partners to develop very innovative R&D projects, to find the best innovative technology, patent or scientific expertise, or to set up and locate in Alsace region.

Alsace BioValley has also agreements with CQDM (Quebec), MLSC (Massachusetts – USA), JBA (Japan Bioindustry Association) and Biopro (Germany).

www.alsace-biovalley.com



Conectus Alsace was the first SATT (Accelerator of Technology Transfer) that

has emerged in France within the Call for Projects of the Program "Investments for the future".

100% funded by the State through the National Valorization Fund operated by the French National Research Agency, Conectus Alsace operates under the private law statute, whose shareholders include: the University of Strasbourg, the CNRS, the University of Haute-Alsace, Inserm, INSA of Strasbourg, the ENGEES and the Caisse des Dépôts et Consignations that brings the participation of the State.

www.conectus.fr

Who will you meet?



35 %

Technology transfer professionals, IP and licensing / Research institutes / Academia

Ascenion, Aviesan, INPI, Inserm Transfert, Karolinska Institute, King's College London, Max Planck Institute of Molecular Cell Biology and Genetics, Oxford University, Pasteur Institute, SATT Network...



35 %

Biotech, R&D services companies

Adocia, ADX NeuroSciences, Aptuit, Atlanbio, Cellectis, Eurofins, Galapagos, Genfit, LFB, Magnomics, Menarini, Syngulon, Zoetis...

20 %

Pharma, Medtech, IVD companies

AstraZeneca, Bio-Rad ABD Serotec, Boehringer Ingelheim, GSK, Ipsen Innovation, J&J Innovation, Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi...

10 %

Investors, Professional services & Consulting

Absiskey, Alma Consulting, De Gaulle Fleurance & Associés, Erdyn, Index Ventures, Karolinska Development, Lonza, Quintiles...

48 hours to find the perfect match and speed up innovation



Identify

your potential partners



Pre-schedule

your meetings



Meet

with high-level international actors

Through its business convention, BioFIT enables its attendees to meet during pre-screened one-to-one meetings in order to engage new partnerships, foster the emergence of collaborative projects and boost up licensing deals.

Thanks to the renowned software partneringONE, powered by EBD Group, BioFIT's participants will get the chance to meet up to 30 potential partners over 2 days.

leis Over 2 days.

powered by



a product of EBDGROUP

TechnoMarket & Presenting Technologies



You have an innovative product or technology?

The SATT network (the association of the French TTOs) & BioFIT launch the TechnoMarket & Presenting technologies sessions aiming at fostering alliances and business development opportunities on innovative projects related to human or animal health in the following categories:

- Cardiometabolic diseases
- Devices / Imaging
- Immunology / Oncology
- Infectious diseases / Vaccines

Are you stemming from a university or a public research institute? Apply for the TechnoMarket and Presenting technologies sessions to present an innovative product, technology, knowhow or research result.





Call for application!

Apply online before mid October

Supported by:





CONFERENCE **PROGRAM**

PLENARY SESSION

" Who drives innovation in life sciences: academia or industry? "

Jochen Maas 💳

General Manager, Research & Development Germany, Sanofi

Marisol Quintero

CEO, BioOncotec

John Carroll

Editor-in-chief, FierceBiotech

Kurt Hertogs

Head Platform Innovation & Incubator Strategy, Johnson & Johnson



Track 1

" Best practices in collaborative research "



INTRODUCED BY

Adrian CARTER

Corporate Vice-President, Global Research Networking, Boehringer Ingelheim (DE)

" Recent developments such as mobile health devices and big data are transforming the way we translate medical advances into new medicines. This track highlights how academia and industry are taking a more open and networked collaboration approach to improve the quality and richness of biomedical research.

THEY WILL SHARE THEIR EXPERIENCE:

Max Fehlmann,

Jon de Vlieger,

Ulf Nehrbass, Hitesh Sanganee,

Isabelle Dieuzy, Magda Chlebus,

Lee Wen Hwa,

<u>Jan van Schueren,</u> Jutta Roth,

Maria Bobadilla,

Senior Vice President, Head of Vaccine Discovery & Development GSK

CEO, Neomed

Call Director of the European Lead Factory,

TI Pharma

Director, Ksilink

Director Emerging Innovations group,

AstraZeneca

Director Strategic Alliances, Zoetis Director Science Policy, IMI/EFPIA


Alliance Manager Director, SGC

CEO, Firalis

Discovery Site Head, Galapagos Business Development Manager,

University of Oxford

Senior Director, Extending Innovation Network, Roche



Track 2

"Key issues in licensing and tech transfer "



INTRODUCED BY

Ivan BAINES

Chief Operating Officer, Max Planck Institute of Molecular Cell Biology and Genetics (DE)

" Pharma and biotech are looking increasingly towards academia for open innovation, explorative research and early stage discovery. But is academia prepared? Are there the models and mechanisms in place for sufficiently professionalized licensing and technology transfer? What about spin-outs and startups? Are the founding terms reasonable or a kiss of death? This track will challenge the current status of academia - industry relations "

THEY WILL SHARE THEIR EXPERIENCE:

Mike Johnson, Divisional Director, MRC Technology Kishna Kalicharran, Executive Director External Alliances,

MerckSerono CEO, ADX Neurosciences Christian Stein, President, ASTP-Proton

<u>Jaromir Zahradka,</u> Business Development Manager, IOCB TTO Cécile Théard-Jallu, Partner Attorney,

De Gaulle Fleurance et Associés Carl Jessop, Due Diligence Director, AstraZeneca Martin Cadman, Scientific Licensing Director, GSK

Matthias Stein-Gerlach, Patent & Licensing Manager, Max-Planck-Innovation

Erik Vane, General Manager, ASTP-Proton Philippe Borne, Regional Representative in Strasbourg,

INPI Alsace Diane Seimetz, Co-Founder, Biopharma Excellence

Timo Minssen, Associate Professor, University of Copenhagen



Track 3

" **Early stage innovation:** identify the right funding sources



INTRODUCED BY

Gunilla EKSTRÖM

Vice President Operations, Karolinska Development (SE)

"It is critical to find funding for early stage innovation, and it is challenging to know what sources are available. Funding in the future will most certainly look different from today. What are the trends? It is therefore important to learn from others, to get inspiration, and to get ideas on different solutions both in the US and Europe."

THEY WILL SHARE THEIR EXPERIENCE:

Sara Nunez-Garcia, Associate, Sofinnova

Garold Breit, YenChen Huang,

Serge Braun,

Robin Rasor,

Olivier Arnaud, Sohini Chowdury,

Mohammed Charki,

Cormac Sheridan,

CEO, Breit Ideas

Senior Assistant VP, Diamond Capital Scientific Director, AFM-Téléthon Managing Director of Licensing,

University of Michigan

European Director of Research, JDRF

Senior Vice President, Research Partnerships,

The Michael J. Fox Foundation

Research & Development Partnerships

Director, Sanofi

Journalist, BioWorld Today

Day one Tuesday, December 1st

()	TRACK 1: Best practices in collaborative research	TRACK 2: Key issues in licensing and tech transfer	TRACK 3: Early stage innovation: identify the right funding sources	TechnoMarket & Presenting Technologies session	Partnering	
8:30 am 9:00 am	Registration and Exhibition opening/ Welcome coffee					
9:00 am 10:30 am	Getting close to the action: new collaborative models to source innovation				One-to-one meetings	
10:30 am 10:45 am	Coffee break					
10:45 am 12:30 pm	PLENARY SESSION: Who drives innovation in life sciences: academia or industry?					
12:30 pm 2:00 pm	🔀 Lunch					
2:00 pm 3:30 pm	How can Open Innovation be a powerful driver for the OneHealth dynamics?	Shaping the future of Open Innovation: does the IP legal framework need a remodeling?	US vs Europe vs Asia: how do VCs assess risk?	Presenting	۰,۰	
3:30 pm 4:00 pm	Coffee break				One-to-one	
4:00 pm 5:30 pm		Networks and alliances with the industry: how can TTOs contribute to their success?	The funding challenge: find alternative approaches to financing innovation	Presenting	meetings	
7:00 pm	▼ BioParty					

Day two Wednesday, December 2nd

		Conferences	ferences		
()	TRACK 1: Best practices in collaborative research	TRACK 2: Key issues in licensing and tech transfer	TRACK 3: Early stage innovation: identify the right funding sources	TechnoMarket & Presenting Technologies session	Partnering
8:30 am 9:00 am	Registration and Exhibition opening/Welcome coffee				
9:00 am 10:30 am		University spin-offs: how to optimize the business and university interests/ is it easy to balance?	How to partner more efficiently with patient groups, charities & foundations?	Presenting	
10:30 am 11:00 am	Coffee break				
11:00 am 12:30 pm		Capacity building by ASTP-Proton	Does crowdfunding have a place in drug development?	Presenting	One-to-one meetings
12:30 pm 2:00 pm	☆ Lunch				meemys
2:00 pm 3:30 pm	Precompetitive collaborations: sharing knowledge, but is there a tangible outcome?	How to implement and perform effective due diligence?			
3:30 pm 4:00 pm	Coffee break				
4:00 pm 5:30 pm	Four hands on the steering wheel: How are academia? industry alliances managed?				

Hosted events

Several events running the day before and during BioFIT will bring together stakeholders in Animal and Human health, Diabetes and Innovation Related Services.



December 1st & 2nd, 2015

2 days of networking and face-to-face meetings between research departments of the veterinary medicine & diagnostics industry and public research, as well as biotechnology companies. Initiated by SIMV, the French syndicate for the animal health industry.

150 delegates / 30 companies / 40 academic teams





November 30th to December 2nd, 2015

A one-day conference on November 30th organized by the French Association of Outsourcing and Innovative Companies to enhance sustainable collaboration between European industrial life sciences and R&D stakeholders. 2 days of partnering during BioFIT on December 1st & 2nd.

100 delegates / 50 companies

Extra fees will be applied to access AFSSI conferences on November 30th





BioValley Day

November 30th, 2015

International Life Sciences players will have the opportunity to discover some of the most innovative academic and industrial actors from the Franco-German-Swiss BioValley region:

- World-class research institutes
- Innovative practices and trends in minimally and imageguided surgery
- 15 promising Life Sciences start-ups looking for funding

70-100 participants



Nov. 30th & Dec. 1st

Innovation in Diabetes: European Action Summit

What is IDEA Summit?

Unique European event initiated by Lund University Diabetes Centre, AstraZeneca, Sanofi, Novo Nordisk, but also supported by Ascenion, Lilly and Genfit, IDEA Summit is dedicated to academia-industry collaborations and technology transfer in the field of Diabetes. The event brings together Pharma, Biotech, TTOs, Academic Scientists and non-profit Organizations to foster innovation by bridging the industry/academia gap and stimulating collaborative research.

IDEA Summit offers:

- **November 30**th: a conference program focused on collaborative research, patient empowering and the latest innovations in the field of diabetes
- **December 1st:** one-to-one partnering meetings provided by BioFIT enabling Pharma, Biotech, TTOs & Academic Scientists to explore licensing & collaborative opportunities
- December 2nd: possibility to continue the partnering activity during BioFIT

Organized by:







Preliminary Conference Program

Conference 1 · · · ·

"Pre-competitive consortia & bilateral collaborations:

are these classic models enough to speed up innovation? "

Conference 2

"How to bridge the gap between research and clinic:

an overview of national initiatives "

Conference 3 · · · · · ·

" Patient empowering:

how can they get more involved in future treatment solutions and funding diabetes research? "

Conference 4

"Most successful/innovative start-ups & SMEs in 2014/2015 in diabetes:

find out their success story and financing map "

They will share their experience

- Anke Schulte, Head of Islet Biology , Diabetes Division, Sanofi
- Bernard Thorens, Professor, University of Lausanne
- Karin Conde-Knape, Vice President of Cardiovascular & Metabolic Scientific Innovation, J&J Innovation
- Stefanie Possekel, Director Technology Management, Ascenion
- Thomas Gunnarsson, Project Manager, Lund University Diabetes Centre
- Soffia Gudbjörnsdottir, Director, Swedish National Diabetes Register
- Magda Gunn, Scientific Project Manager, IMI Innovative Medicines Initiative
 - John Carroll, Editor-in-Chief, FierceBiotech

Learn more about the event, conferences and speakers: www.idea-summit-diabetes.com

www.ided-sommi-didbeles.com

In collaboration with:









Supported by:











They support us

Gold sponsors





Silver sponsors

Catalent



Bronze sponsors















Contributing sponsors









































Supporters

































































































CONTACTS

Margaux SATOLA
Business Development Manager
msatola@eurasante.com
+33 (0)3 59 39 01 82

Ramona PIRV-CHICIREANU
Conference Coordinator
rpirv@eurasante.com
+33 (0)3 59 39 01 84

EVENT VENUE

Strasbourg Convention Centre Palais de la Musique et des Congrès Place de Bordeaux 67082 Strasbourg, France

Institutional Partners















